Phase I study of oral GZ17-6.02 in patients with advanced solid tumors or lymphoma

被引：0
|
作者：
Mita, A. [1 ]
Mita, M. [1 ]
Tsai, F. [2 ]
Moore, R. P. [3 ]
Bailes, J. [3 ]
Matrana, M. [4 ]
机构：
[1] Cedars Sinai Med Ctr, Oncol, Los Angeles, CA 90048 USA
[2] Honor Hlth Res & Innovat Inst, Oncol, Scottsdale, AZ USA
[3] Genzada Pharmaceut, R&D, Hutchinson, KS USA
[4] Ochsner Canc Inst, Oncol, New Orleans, LA USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1070
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
548P
引用
收藏
页码：S609 / S610
页数：2
相关论文
共 50 条
  • [41] Phase I study of safety, tolerability, and pharmacokinetics of pazopanib in combination with oral topotecan in patients with advanced solid tumors
    Kerklaan, Bojana Milojkovic
    Lolkema, Martijn P. J. K.
    Devriese, Lot A.
    Voest, Emile E.
    Nol-Boekel, A.
    Mergui-Roelvink, M.
    Mykulowycz, Kristine
    Stoebenau, Joseph E.
    Fang, Lei
    Legenne, Philippe
    Wissel, Paul Stephen
    Smith, Deborah A.
    Giantonio, Bruce J.
    Schellens, Jan H. M.
    Witteveen, Petronella
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors
    Muindi, Josephia R.
    Johnson, Candace S.
    Trump, Donald L.
    Christy, Renee
    Engler, Kristie L.
    Fakih, Marwan G.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 65 (01) : 33 - 40
  • [43] A PHASE I STUDY OF RIDAFOROLIMUS, THE ORAL MTOR INHIBITOR, AS A SINGLE AGENT IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Seki, Y.
    Yamamoto, N.
    Goto, Y.
    Shibata, T.
    Tanioka, M.
    Nokihara, H.
    Yamada, Y.
    Azuma, H.
    Noguchi, K.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2010, 21 : 174 - 174
  • [44] Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors
    Noboru Yamamoto
    Hiroshi Nokihara
    Yasuhide Yamada
    Kazunori Uenaka
    Risa Sekiguchi
    Takeshi Makiuchi
    Christopher A. Slapak
    Karim A. Benhadji
    Tomohide Tamura
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1645 - 1655
  • [45] A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors
    Fakih, Marwan G.
    Trump, Donald L.
    Muindi, Josephia R.
    Black, Jennifer D.
    Bernardi, Ronald J.
    Creaven, Patrick J.
    Schwartz, James
    Brattain, Michael G.
    French, Renee
    Johnson, Candance S.
    CLINICAL CANCER RESEARCH, 2007, 13 (04) : 1216 - 1223
  • [46] Phase I study of CFI-402257, an oral TTK inhibitor, in patients with advanced solid tumors.
    Cescon, David W.
    Hansen, Aaron Richard
    Razak, Albiruni Ryan Abdul
    Stayner, Lee-Anne
    Hilton, John Frederick
    Renouf, Daniel John
    Denny, Trisha
    Fletcher, Graham
    Mak, Tak W.
    Bray, Mark R.
    Bedard, Philippe L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [47] Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors
    Minami, Hironobu
    Kawada, Kenji
    Ebi, Hiromichi
    Kitagawa, Koichi
    Kim, Yon-il
    Araki, Kazuhiro
    Mukai, Hirofumi
    Tahara, Makoto
    Nakajima, Hikaru
    Nakajima, Keiko
    CANCER SCIENCE, 2008, 99 (07): : 1492 - 1498
  • [48] A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors
    Josephia R. Muindi
    Candace S. Johnson
    Donald L. Trump
    Renee Christy
    Kristie L. Engler
    Marwan G. Fakih
    Cancer Chemotherapy and Pharmacology, 2009, 65 : 33 - 40
  • [49] PHASE I STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF TWO CAPSULE FORMULATIONS OF IXAZOMIB, AN ORAL PROTEASOME INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS OR LYMPHOMA.
    Hanley, M. J.
    Gupta, N.
    Venkatakrishnan, K.
    Bessudo, A.
    Sharma, S.
    O'Neil, B.
    Wang, B.
    Hui, A.
    Nemunaitis, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S81 - S81
  • [50] A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors
    Ruth Plummer
    Ayman Madi
    Melinda Jeffels
    Heike Richly
    Bahar Nokay
    Stephen Rubin
    Howard A. Ball
    Steve Weller
    Jeffrey Botbyl
    Diana M. Gibson
    Max E. Scheulen
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 93 - 101
12345